Last reviewed · How we verify
Recombinant erythropoietin stimulating protein
Recombinant erythropoietin stimulating protein is a Small molecule drug developed by Shenyang Sunshine Pharmaceutical Co., LTD.. It is currently in Phase 1 development. Also known as: Recombinant erythropoietin stimulating protein injection.
At a glance
| Generic name | Recombinant erythropoietin stimulating protein |
|---|---|
| Also known as | Recombinant erythropoietin stimulating protein injection |
| Sponsor | Shenyang Sunshine Pharmaceutical Co., LTD. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial) (PHASE2)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia (PHASE3)
- ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions (PHASE3)
- Vafseo Outcomes In-Center Experience (PHASE3)
- A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions (PHASE3)
- Choices About Genetic Testing And Learning Your Risk With Smart Technology (NA)
- Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant erythropoietin stimulating protein CI brief — competitive landscape report
- Recombinant erythropoietin stimulating protein updates RSS · CI watch RSS
- Shenyang Sunshine Pharmaceutical Co., LTD. portfolio CI
Frequently asked questions about Recombinant erythropoietin stimulating protein
What is Recombinant erythropoietin stimulating protein?
Recombinant erythropoietin stimulating protein is a Small molecule drug developed by Shenyang Sunshine Pharmaceutical Co., LTD..
Who makes Recombinant erythropoietin stimulating protein?
Recombinant erythropoietin stimulating protein is developed by Shenyang Sunshine Pharmaceutical Co., LTD. (see full Shenyang Sunshine Pharmaceutical Co., LTD. pipeline at /company/shenyang-sunshine-pharmaceutical-co-ltd).
Is Recombinant erythropoietin stimulating protein also known as anything else?
Recombinant erythropoietin stimulating protein is also known as Recombinant erythropoietin stimulating protein injection.
What development phase is Recombinant erythropoietin stimulating protein in?
Recombinant erythropoietin stimulating protein is in Phase 1.
Related
- Manufacturer: Shenyang Sunshine Pharmaceutical Co., LTD. — full pipeline
- Also known as: Recombinant erythropoietin stimulating protein injection
- Compare: Recombinant erythropoietin stimulating protein vs similar drugs
- Pricing: Recombinant erythropoietin stimulating protein cost, discount & access